APQ Health
APQ Health provides FDA-cleared, AI-powered software that automatically quantifies coronary plaque and stenosis from CT angiography images. The Autoplaque platform is validated against invasive IVUS with an ICC of 0.95 and is backed by over 100 peer-reviewed publications, including the landmark SCOT-HEART trial, enabling clinicians to better predict cardiac risk.
- Healthcare Technology
- Digital Health
- Artificial Intelligence
- Data & Analytics
- Software Only
Funding
Founders
Founder details are not available yet.
Product
Problem
Traditional coronary plaque assessment relies on invasive procedures like IVUS or manual interpretation of CT angiography, which is time-consuming, operator-dependent, and often inconsistent. This limits the ability to accurately quantify plaque burden and identify high-risk plaque features that predict future heart attacks, particularly in outpatient and preventive cardiology settings.
Solution
APQ Health provides Autoplaque, an FDA-cleared, AI-driven software platform that automatically analyzes 3D coronary CT angiography images to quantify plaque volume, characterize plaque composition, and measure stenosis severity. The platform uses deep learning algorithms validated in international multicenter studies, achieving an intraclass correlation coefficient of 0.95 against invasive IVUS. Autoplaque generates reproducible, quantitative results that help clinicians identify patients at elevated risk for myocardial infarction, including those with low-attenuation noncalcified plaque burden. The software is supported by extensive peer-reviewed research, including the SCOT-HEART trial, and is designed to integrate into existing radiology and cardiology workflows.
Target Audience
Primary users are cardiologists, radiologists, and preventive cardiology clinics that perform coronary CT angiography and need automated, evidence-based plaque quantification for risk assessment and treatment planning. The platform also serves academic medical centers and clinical research organizations conducting multicenter trials.
Features
- Fully automated deep learning-based plaque quantification from CCTA, including total plaque volume, low-attenuation noncalcified plaque, and calcified plaque
- Stenosis severity measurement with head-to-head validation against invasive IVUS (ICC 0.95)
- High scan-rescan repeatability for longitudinal monitoring of disease progression or treatment response
- AI-enabled risk stratification using thresholds validated in multicenter trials, including the SCOT-HEART study (low-attenuation NCP >4%: HR 4.65)
- Backed by 100+ peer-reviewed publications and validated across diverse real-world cohorts and multi-ethnic populations
- Exclusive license to the Autoplaque technology with FDA clearance for clinical use